Seletalisib is a selective Phosphatidylinositol 3 kinase delta inhibitor originated by UCB. It is an immunomodulator. Phaes I clinical trials for Plaque psoriasis, phaes II clinical trials for Sjogren's syndrome and phaes III clinical trials for Immunodeficiency disorders is on-going.
Products > Drug Discovery > Inhibitor | Products > Drug Discovery > Inhibitor | Cancer | PI3K
Please leave a message for us or use the following ways to contact us, we will reply to you as soon as possible, and provide you with the most sincere service, thank you.
日本语
한국어
Français
Deutsch
España
Türkiye